PUBLIC COMPANY
save$SVRASavara Inc
$SVRA5.7000+2.33%Austin, TX, USupdated 3h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1pre_registration
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
- —Molgramostim Nebulizer Solution Expanded Access Program Protocol
- phase3Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- phase3Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
- phase2Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Mar 18, 26tax coverLowrance David L · Chief Financial Officer31,885 sh
- Mar 18, 26option exerciseLowrance David L · Chief Financial Officer130,650 sh
- Mar 18, 26tax coverLowrance David L · Chief Financial Officer24,174 sh
- Mar 18, 26option exerciseLowrance David L · Chief Financial Officer80,684 sh
- Mar 18, 26tax coverLowrance David L · Chief Financial Officer23,661 sh
- Mar 18, 26option exerciseLowrance David L · Chief Financial Officer75,000 sh
🐶 Hiring Signal
next earnings Aug 13, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 12m ago
Found something off?
comments(0)
5-min edit window · permanent after that